Atai Life Sciences Advances Vls-01 For Treatment-Resistant Depression

atai Life Sciences advances VLS-01 for treatment-resistant depression

Proactive Investors

atai Life Sciences outlines key milestones in psychedelic therapy for depression in 2023 and 2024

Proactive Investors

atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression

Proactive Investors

Atai Life Sciences 'bringing innovation to mental healthcare and treatment addiction'

Proactive Investors

Florian Brand (Atai Life Sciences): Psychedelics – The New Psychiatric Frontier | Slush 2021

Florian Brand Talks of Innovation in Mental Healthcare to Tackle Depression, Anxiety and Addiction

Atai Life Sciences founder on using psychedelics to treat mental illness

CNBC Television

Psychedelics for Depression: The Promise, Risks, & Costs - Srinivas Rao (Mapping the Mind 2019)

Mapping the Mind

Psilocybin Found To Rapidly Improve Depressive Symptoms In Patients

Treatment of Resistant Depression

MWAETC: Project ECHO

The stock of psychedelics giant Atai is tumbling after a treatment failed to help patients |#shorts

Klinik & Harrow Health - A Digital triage case study 1

Klinik Healthcare Solutions

Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder

Management of Treatment Resistant Depression | Mental Health Professional Webinar

Conducting FDA Approved Protocol For Treatment Of Depression l Protocol Preview

JoVE (Journal of Visualized Experiments)

The Value of Med Tech in Treating Children with Diabetes

Atai shares pop after earnings: Company's CEO talks about mental health and psychedelics

CNBC Television

ViaCyte

Alliance for Regenerative Medicine

The cycle of basic science and clinical trials – CVR Onlife

European Society of Cardiology

ViaCyte

Alliance for Regenerative Medicine